Literature DB >> 8215620

Methotrexate osteopathy in rheumatic disease.

S J Preston1, T Diamond, A Scott, M R Laurent.   

Abstract

OBJECTIVE: To determine whether two adults with stress fractures receiving low weekly doses of methotrexate had methotrexate osteopathy. CASE REPORTS: Two adult patients developed features consistent with methotrexate osteopathy while receiving low weekly doses of methotrexate.
METHODS: Iliac crest biopsy samples were taken and bone histomorphometry carried out.
RESULTS: Symptoms resolved when the methotrexate was discontinued. Bone histology showed changes consistent with osteoblast inhibition by methotrexate.
CONCLUSIONS: When given in low doses for prolonged periods, methotrexate may have adverse effects on bone, particularly in post-menopausal women.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215620      PMCID: PMC1005115          DOI: 10.1136/ard.52.8.582

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems.

Authors:  M Nesbit; W Krivit; R Heyn; H Sharp
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

2.  Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors?

Authors:  T Diamond; D Stiel; S Posen
Journal:  Ann Intern Med       Date:  1989-03-15       Impact factor: 25.391

3.  Fractures in children treated with methotrexate for leukemia.

Authors:  S Stanisavljevic; A L Babcock
Journal:  Clin Orthop Relat Res       Date:  1977-06       Impact factor: 4.176

4.  Methotrexate-induced bone pain in childhood leukemia.

Authors:  S O'Regan; D K Melhorn; A J Newman
Journal:  Am J Dis Child       Date:  1973-10

5.  Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission.

Authors:  A H Ragab; R S Frech; T J Vietti
Journal:  Cancer       Date:  1970-03       Impact factor: 6.860

6.  Methotrexate.

Authors:  N Christophidis
Journal:  Clin Rheum Dis       Date:  1984-08

7.  Methotrexate osteopathy.

Authors:  A M Schwartz; J C Leonidas
Journal:  Skeletal Radiol       Date:  1984       Impact factor: 2.199

Review 8.  Methotrexate therapy in the treatment of rheumatoid arthritis.

Authors:  J M Kremer
Journal:  Rheum Dis Clin North Am       Date:  1989-08       Impact factor: 2.670

9.  Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model.

Authors:  G E Friedlaender; R B Tross; A C Doganis; J M Kirkwood; R Baron
Journal:  J Bone Joint Surg Am       Date:  1984-04       Impact factor: 5.284

10.  The effects of methotrexate (MTX) on bone. A densitometric study conducted on 59 patients with MTX administered at different doses.

Authors:  S Gnudi; L Butturini; C Ripamonti; M Avella; G Bacci
Journal:  Ital J Orthop Traumatol       Date:  1988-06
  10 in total
  13 in total

1.  Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism.

Authors:  Addolorata Corrado; Anna Neve; Arcangela Marucci; Annamaria Gaudio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2014-08-23       Impact factor: 3.984

2.  Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study.

Authors:  Katsumitsu Arai; Tadamasa Hanyu; Hiroya Sugitani; Takehiro Murai; Junichi Fujisawa; Kiyoshi Nakazono; Naoki Kondo; Naoto Endo
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 3.  Osteoporosis in rheumatoid arthritis.

Authors:  Y Suzuki; Y Mizushima
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 4.  Methotrexate osteopathy: five cases and systematic literature review.

Authors:  F Robin; S Cadiou; J-D Albert; G Bart; G Coiffier; P Guggenbuhl
Journal:  Osteoporos Int       Date:  2020-10-30       Impact factor: 4.507

Review 5.  Drug-induced disorders of bone metabolism. Incidence, management and avoidance.

Authors:  G Jones; P N Sambrook
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 6.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

7.  Associations between methotrexate treatment and methylenetetrahydrofolate reductase gene polymorphisms with incident fractures in Japanese female rheumatoid arthritis patients.

Authors:  Wako Urano; Takefumi Furuya; Eisuke Inoue; Atsuo Taniguchi; Tomohiko Urano; Shigeru Kotake; Chieko Sekita; Satoshi Inoue; Masako Hara; Shigeki Momohara; Naoyuki Kamatani; Hisashi Yamanaka
Journal:  J Bone Miner Metab       Date:  2009-03-31       Impact factor: 2.626

Review 8.  Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.

Authors:  B F Ricciardi; J Paul; A Kim; L A Russell; J M Lane
Journal:  Osteoporos Int       Date:  2012-09-07       Impact factor: 4.507

9.  Risk of fragility fracture among patients with late-onset psoriasis: a UK population-based study.

Authors:  Z Paskins; R Whittle; A Abdul Sultan; S Muller; M Blagojevic-Bucknall; T Helliwell; J Packham; S Hider; E Roddy; C Mallen
Journal:  Osteoporos Int       Date:  2018-03-24       Impact factor: 4.507

10.  No deleterious effect of low dose methotrexate on titanium implant osseointegration in a rabbit model.

Authors:  Janaina Badin Carvas; Rosa Maria Rodrigues Pereira; Eloisa Bonfá; Celey Aparecida Silveira; Luiz Lapa Lima; Valéria de Falco Caparbo; Suzana Beatriz Veríssimo de Mello
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.